Mauna Kea Technologies announces the availability of preparatory documents for the General Meeting of Shareholders dated June 2, 2022 and clarifies the conditions for participation


Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext:MKEA) (” Company “), inventor of Cellvizio®, a multidisciplinary platform for confocal laser probe-and-needle endomicroscopy (p/nCLE), announces the availability today of preparatory documents for the Joint General Meeting on June 2, 2022, which will be held at 2:00 pm at the company’s registered office .

Notice of the meeting, including the agenda, draft decision text, and how to participate in the meeting and vote at the meeting, was published in the Bulletin of Legal Announcements Binding (BALO) April 25, 2022 Bulletin #°49, Announcement 2201108.

This notice of the meeting, as well as documents or information related to the Joint General Meeting, and the unified voting form are available on the Company’s website in the section dedicated to the General Meeting, in the “Investors” section at the following address: https: //www

Any shareholder may also obtain, under the conditions provided for in articles R.225-88 and R.225-89 of the French Commercial Code, the documents referred to above by a simple written request addressed to the registered office of the Company, located at 9 Rue d’ Enghien – 75010 Paris. However, the Company invites shareholders, as a matter of priority, to send all their inquiries electronically to the following address: [email protected]

Voting methods

Shareholders of the Company are invited to exercise their voting rights prior to the General Meeting in accordance with the procedures set out below and detailed in the notice of the meeting published today on the Company’s website:

Voting by mail or proxy (with the issuance of a power of attorney to the chairman of the meeting or a third party, or without specifying a power of attorney) electronic VOTACCESS is available and should be used as a priority. The secure VOTACCESS platform will be open from Monday, May 16, 2022 at 09:00 (Paris time) and close on Wednesday, May 1.uh June 2022 at 3:00 pm (Paris time). However, shareholders are strongly advised not to wait until the last few days to enter their voting instructions;

Voting in absentia or by proxy by mail ;

– Shareholders can also attend the meeting in person.

In addition, shareholders have the opportunity to submit written questions to the email address [email protected] or [email protected] before the General Meeting, until midnight on May 27, 2022, and confirming their status as shareholders.

Given the medical context of the Covid-19 epidemic, procedures for holding a General Meeting and physically participating in said meeting may change depending on medical and/or legal requirements prior to the day of the General Meeting. Therefore, shareholders are requested to refer regularly to the General Meeting section of the Company’s website ( where these conditions will be clarified and updated. updated if necessary.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and markets Cellvizio®, a real-time in vivo cellular imaging platform. This technology provides unique in vivo cellular imaging that allows clinicians to track disease progression over time, assess responses as they occur, classify areas of uncertainty, and guide surgical interventions. The Cellvizio platform is used in many countries around the world and in several medical specialties and changes the way doctors diagnose and treat patients. For more information visit

A warning

This press release contains forward-looking statements relating to Mauna Kea Technologies and its business. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no guarantees can be made as to whether the forward-looking statements expressed in these forward-looking statements will be achieved, which are subject to risks, including those described in the Mauna Kea Technologies background paper filed by the Autorité des Marchés financiers (AMF) in June. September 17, 2021 under number D-21-0566 and the 2020 Universal Registration Document Amendment filed with AMF on September 17, 2021, both of which are available on the Company’s website (, and only to the development of the economic situation, financial markets and markets in which Mauna Kea Technologies is present. The forward-looking statements contained in this press release are also subject to risks unknown to Mauna Kea Technologies or which Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could cause the actual results, financial conditions, performance or achievements of Mauna Kea Technologies to differ materially from the results, financial conditions, performance or achievements set forth in these forward-looking statements. This press release and the information contained therein does not constitute an offer to sell or subscribe, or an offer to order a purchase or subscription for shares of Mauna Kea Technologies in any country.


NewCap – Investor Relations
Thomas Grosjean

+33 (0)1 44 71 94 94

[email protected]